Genzyme sells research line
This article was originally published in Clinica
Genzyme General is to divest its research products business to TECHNE for around $65 million before taxes. The purchase will consist of $24.8 million in cash, $17 million of TECHNE shares and estimated royalties of $23.7 million on TECHNE's biotechnology group sales for the next five years. The companies expect to close the transaction on July 1.
You may also be interested in...
ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs. See what the CFO said about it here.
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.